On August 26, REMEGEN rose 5.04% in regular trading, trading at HK$83.7/share, with turnover of HK$86.20 million.

On the news front, the company disclosed its interim report on August 24, reporting first-half revenue of RMB 5.853 billion, up 433.11% year-over-year, and net profit attributable to shareholders of RMB 4.662 billion, swinging from a loss of RMB 450 million in the same period last year. The dramatic turnaround was primarily driven by technology licensing income recognized from the exclusive licensing agreement signed with AbbVie for RC148, with the upfront payment alone contributing substantial profits. In addition, domestic sales of core products Telitacicept and Disitamab Vedotin continued to grow.

The broader Biotechnology sector rallied strongly on the same day, with INNOVENT BIO up 11.39%, EVEREST MED up 9.07%, AKESO up 7.14%, and CANSINOBIO up 18.22%, providing additional sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)